-
Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious
Thursday, July 17, 2025 - 11:37am | 469Shares of Johnson & Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report. Here are some key analyst takeaways. BofA Securities analyst Tim Anderson reiterated a Neutral rating, while raising the price target from $161 to $175. Guggenheim Securities...
-
Johnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'
Wednesday, April 16, 2025 - 11:12am | 558Johnson & Johnson (NYSE:JNJ) reported upbeat first-quarter results on Wednesday. Here are some key analyst takeaways. Goldman Sachs On Johnson & Johnson Analyst Asad Haider maintained a Buy rating and price target of $172. Despite Stelara sales declining due to the arrival of biosimilars in...
-
Intuitive Surgical Posts Q3 Earnings Beat, These Analysts Raise Forecasts On DV5 Uptake
Friday, October 18, 2024 - 12:19pm | 768Intuitive Surgical, Inc. (NASDAQ:ISRG) Thursday reported upbeat earnings for its third quarter. The company reported its results amid an exciting earnings season. Here are some key analyst takeaways. RBC Capital Markets analyst Shagun Singh reiterated an Outperform rating, while raising the price...
-
Johnson & Johnson Has Potential To Drive Its Pharma And MedTech Franchises, Says Bullish Analyst
Thursday, October 5, 2023 - 12:40pm | 252Shares of Johnson & Johnson (NYSE: JNJ) recovered slightly in early trading on Thursday, after tanking in the previous session. The company is “uniquely positioned with Pharma and MedTech under one umbrella,” according to RBC Capital Markets. The Johnson & Johnson Analyst:...
-
Intuitive Surgical Soars On Stellar Q1 Results: Analysts Boost Price Targets Amid Robust Procedure Growth
Wednesday, April 19, 2023 - 12:06pm | 619Shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) surged in after-hours trading on Tuesday, following the release of the company’s upbeat results for the first quarter. RBC Capital Markets On Intuitive Surgical Analyst Shagun Singh maintained an Outperform rating, while raising the price...
-
4 Analysts Takeaways From Johnson & Johnson's Quarterly Results: What Investors Need To Know
Wednesday, July 20, 2022 - 12:02pm | 406Johnson & Johnson (NYSE: JNJ) reported a 3% growth in net sales to $24.02 billion, surpassing the consensus estimate of $23.81 billion, and a 4.4% growth in adjusted earnings to $2.59 per share, beating Street expectations of $2.57 per share. Raymond James On Johnson & Johnson: Analyst...
-
Intuitive Surgical Has A 'Multi-Year Growth Runway,' RBC Capital Says: What Are The Catalysts?
Friday, March 25, 2022 - 2:05pm | 222Intuitive Surgical, Inc. (NASDAQ: ISRG) is a global leader in the robotic-assisted surgery market, which is not only large — it is estimated at more than $6 billion — but also the most underpenetrated and fastest-growing among the medical device sub-markets, according to RBC Capital...